Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
about
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataCost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable.Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?The consequences of cirrhosis in America.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review
P2860
Q28072257-2EA65D8E-5234-4A2E-970B-2AECF6107375Q28550101-1CB1F130-52DB-4222-AD9E-ACECBD3FF4A5Q35606843-4108D962-3B0F-47C2-8163-017134B11A54Q37555115-F92E0F81-4977-4D72-A23B-DD390C699E09Q37629097-F22E495C-3E54-4E0D-AC8F-A01E170020E0Q38470584-6F156598-33CF-40C5-A8FF-D320B45C1156Q38691333-059053C0-F056-4710-8C30-6E47FEC95EB9Q38755073-1CACAB9F-C19B-4D72-8489-BBB9550FA850Q38932103-D43CE71D-44EF-44B0-A8A4-5E2F887AFB9AQ38980602-3EB99834-FE00-49AE-B744-609BFD4493F4Q39002644-038C3C19-496B-4DC9-95B9-0E17C384190FQ39117290-0D928CD5-EF92-4001-BFD1-F5B2A8B32E41Q39462995-C97BA2A7-2E95-448E-AD8C-6237E5EFC138Q40197476-6FB937D7-848C-437C-8D43-9FEE4A8F39ADQ40562865-789F4827-7D41-4417-90A4-033BA6A41286Q40576603-3C406F79-4BC4-416C-B9B3-5A15DE91E0B4Q40604753-5B819D15-78E2-4194-B269-7685755C8373Q40637339-77DF8881-1A52-4A57-8DB2-75B9ACD10370Q40677384-1E84F082-86DE-450F-ADCA-EE6DDB868300Q40690948-980F8BAE-26C8-4822-95E1-70FA9BF333B9Q40720905-B5013242-6BFB-4E0B-B146-0E2DFCFE7990Q41043367-832E6C13-BF34-43FA-A5F3-B6B39DD039D5Q41366537-6C854E2B-9BA7-4C6D-A255-3250CBE09690Q41612169-283A91C9-864D-4263-A037-6918CD2AA382Q43095281-34A71461-33D9-4337-9ECE-C7B8B0A9DCDEQ50280201-9A6EB3E7-027E-4926-9321-E0131E375E17Q50280206-5394268C-7584-4792-832D-DEA47F03BE27Q53709364-3A5F341F-8E81-474F-B259-5BC002AC3BB7Q55280669-EF642907-F5F8-4443-91F7-582581EF99D7Q57307361-F6D94378-3510-445A-BC7A-1079E9CE01DB
P2860
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cost-effectiveness analysis of ...... C virus genotype 1 infection.
@en
Cost-effectiveness analysis of ...... C virus genotype 1 infection.
@nl
type
label
Cost-effectiveness analysis of ...... C virus genotype 1 infection.
@en
Cost-effectiveness analysis of ...... C virus genotype 1 infection.
@nl
prefLabel
Cost-effectiveness analysis of ...... C virus genotype 1 infection.
@en
Cost-effectiveness analysis of ...... C virus genotype 1 infection.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness analysis of ...... C virus genotype 1 infection.
@en
P2093
P2860
P304
P356
10.1111/APT.12871
P407
P577
2014-07-28T00:00:00Z